Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
28.00
+0.01
(+0.04%)
After-Hours: 20:00
Ambrx Biopharma Cash from Investing (Quarterly): 6.164M for Sept. 30, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 6.164M |
| June 30, 2023 | 9.181M |
| March 31, 2023 | 29.55M |
| December 31, 2022 | 17.74M |
| Date | Value |
|---|---|
| September 30, 2022 | -0.252M |
| June 30, 2022 | -63.43M |
| March 31, 2022 | -0.774M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-63.43M
Minimum
Jun 2022
29.55M
Maximum
Mar 2023
-0.2599M
Average
6.164M
Median
Sep 2023
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -464.00M |
| Axonics Inc | 138.23M |
| Harpoon Therapeutics Inc (DELISTED) | -1.029M |
| Merck & Co Inc | -1.376B |
| RayzeBio inc (DELISTED) | -146.77M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.88M |
| Cash from Financing (Quarterly) | 9.71M |
| Free Cash Flow | -58.82M |
| Free Cash Flow Per Share (Quarterly) | -0.308 |
| Free Cash Flow to Equity (Quarterly) | -19.18M |
| Free Cash Flow to Firm (Quarterly) | -19.18M |
| Free Cash Flow Yield | -0.81% |